Menu Search
Equities

Benchmark Holdings PLC

31B:DEU

Benchmark Holdings PLC

Actions
  • Price (EUR)0.38
  • Today's Change-0.016 / -4.04%
  • Shares traded0.00
  • 1 Year change-36.13%
  • Beta--
Data delayed at least 15 minutes, as of Mar 31 2023 20:50 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Benchmark Holdings plc is an aquaculture biotechnology company. The Company is focused on delivering products and solutions across genetics, advanced nutrition and health. The Company’s segments include Genetics, Advanced Nutrition and Health. The Genetics segment is salmon breeding technology combined with production facilities to provide a range of genetic merit ova. Advanced Nutrition segment manufactures and provides nutrition and health products to the global aquaculture industry. The Health segment is focused on providing health products to the global aquaculture market. The Company has a portfolio of products and solutions, including salmon eggs with specialist genetic traits, shrimp broodstock, tilapia fry, technology enhanced live feed (Artemia), specialist diets, probiotics and sea lice treatments.

  • Revenue in GBP (TTM)172.76m
  • Net income in GBP-28.01m
  • Incorporated2000
  • Employees847.00
  • Location
    Benchmark Holdings PLCBenchmark House, 8 Smithy Wood DriveSHEFFIELD S35 1QNUnited KingdomGBR
  • Phone+44 114 240 9939
  • Websitehttp://www.benchmarkplc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BMK:LSE since
announced		Transaction
value
Benchmark Genetics Iceland hfDeal completed17 Feb 202317 Feb 2023Deal completed-7.16%--
Data delayed at least 20 minutes, as of Mar 31 2023 16:35 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.